Gould Capital LLC Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Gould Capital LLC bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,217 shares of the medical research company's stock, valued at approximately $1,225,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of CRL. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 1.7% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock worth $394,359,000 after acquiring an additional 31,359 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Finally, Earnest Partners LLC grew its holdings in shares of Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company's stock valued at $207,507,000 after purchasing an additional 110,725 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CRL. StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. Redburn Atlantic started coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 price target on the stock. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Finally, Citigroup cut shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and decreased their target price for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $214.38.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Down 2.3 %

CRL stock traded down $4.70 during midday trading on Tuesday, hitting $197.05. The company's stock had a trading volume of 415,502 shares, compared to its average volume of 618,158. The firm has a 50-day simple moving average of $194.19 and a 200-day simple moving average of $203.56. The firm has a market capitalization of $10.08 billion, a P/E ratio of 25.25, a PEG ratio of 4.95 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period last year, the business posted $2.72 earnings per share. Charles River Laboratories International's revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).